Edwards Lifesciences Corporation (NYSE:EW) Receives $93.95 Average PT from Brokerages

Edwards Lifesciences Corporation (NYSE:EW) has been given an average recommendation of “Moderate Buy” by the twenty-seven research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and three have given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $93.9545.

Several equities analysts recently commented on EW shares. Evercore ISI increased their target price on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. Finally, Citigroup restated a “buy” rating and issued a $101.00 price objective (up previously from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th.

Edwards Lifesciences Trading Up 0.1%

Shares of EW stock opened at $86.94 on Thursday. The business has a 50-day moving average price of $84.08 and a two-hundred day moving average price of $79.71. Edwards Lifesciences has a 12-month low of $65.94 and a 12-month high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The firm has a market cap of $50.45 billion, a P/E ratio of 37.47, a price-to-earnings-growth ratio of 3.90 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company’s revenue was up 14.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $84.03, for a total transaction of $85,626.57. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at $1,848,828.06. This trade represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 45,465 shares of company stock valued at $3,804,610 over the last quarter. 0.34% of the stock is owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

A number of institutional investors and hedge funds have recently made changes to their positions in EW. Econ Financial Services Corp purchased a new stake in shares of Edwards Lifesciences during the second quarter valued at $889,000. Randolph Co Inc purchased a new stake in Edwards Lifesciences during the 2nd quarter valued at about $301,000. OMERS ADMINISTRATION Corp grew its stake in Edwards Lifesciences by 97.3% during the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after purchasing an additional 21,950 shares during the last quarter. Pacific Capital Partners Ltd acquired a new position in shares of Edwards Lifesciences in the second quarter valued at about $1,760,000. Finally, Arkadios Wealth Advisors purchased a new position in shares of Edwards Lifesciences in the second quarter worth about $300,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.